According to slide # 34 of a recent presentation from March 8th the company is engaging in a Global SERMO Market Outreach Program. 

http://www.resverlogix.com/upload/media_element/267/01/cowen-healthcare-conference---final.pdf

Slide 34 has a bar graph that indicates 87% of Doctors would perscribe Apabetalone if a large phase III trial showed 25% RRR of MACE, and 90% if the RRR was 90%.

Sermo bills itself as the #1 social network for Doctors in the US and globally:

http://www.sermo.com/

To me that behaviour is more important than any concerns over first line/last line.